Abstract
Self-injection of the injectable contraceptive subcutaneous DMPA* (DMPA-SC, marketed as Sayana® Press) is transforming women’s contraceptive access and autonomy by putting a popular method directly into their hands.
Recent studies in Uganda have found that self-injection is feasible, acceptable, and helps women to continue using the method longer than injections from providers. Moving beyond research, there is a clear need to develop approaches to self-injection delivery that are scalable, sustainable, and accessible to all women.
